Globus Medical price target lowered to $70 from $94 at Stifel

Stifel lowered the firm’s price target on Globus Medical (GMED) to $70 from $94 and keeps a Buy rating on the shares. In April, at least, the business “seems on a better trajectory,” but there will be persisting questions and skepticism that “will not end until the company posts at least one back-on-track quarter,” the analyst tells investors.